EurekAlert! Cancer Research - News Releases

News Releases

Updates every hour. Last Updated: 3-Nov-2026 13:17 ET (3-Nov-2026 18:17 GMT/UTC)

Charles W.M. Roberts, MD, Ph.D., St. Jude president and CEO-elect, named to National Academy of Medicine

St. Jude Children's Research Hospital
Business Announcement

Learn more about St. Jude president and CEO-elect Charles W.M. Roberts, MD, PhD, who is newly named to the National Academy of Medicine.   

Dartmouth Cancer Center director Roy S. Herbst, MD, Ph.D., elected to National Academy of Medicine

Dartmouth Health
Grant and Award Announcement

Roy S. Herbst, MD, PhD, director of the Dartmouth Cancer Center and a professor of microbiology and immunology and of medicine at Geisel School of Medicine, has been elected to the National Academy of Medicine (NAM). One of the highest honors in the fields of health and medicine, NAM recognizes individuals who have demonstrated outstanding professional achievement and commitment to service.

ESMO updates ESCAT framework for precision oncology: new guidance on actionability and resistance biomarkers

European Society for Medical Oncology
Reports and Proceedings

ESMO has published version 2 of the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT), a major update to the internationally recognised precision oncology framework that helps oncologists assess the clinical relevance of molecular alterations and match patients with the most appropriate targeted therapies.

ESMO launches new principles for humanizing scientific reporting to strengthen the communication of cancer research

European Society for Medical Oncology
Reports and Proceedings

ESMO is introducing a new set of principles for speakers presenting at ESMO Congress 2026, designed to strengthen the communication of cancer research and help connect scientific findings more clearly with their relevance to patients.

Kansai Medical University Hospital administers world’s first dose of DS1025 in an international early phase 1 clinical trial

Kansai Medical University
Business Announcement

In an international Phase 1 clinical trial, Kansai Medical University Hospital achieved the “Global First Patient First Dose” milestone by administering the first dose of DS1025, Daiichi Sankyo’s investigational, potential first-in-class CD25 directed antibody drug conjugate. DS1025 contains an immuno-oncology optimized cytotoxic payload to deplete immunosuppressive regulatory T cells (Treg cells) in tumors. This First-in-Human trial will assess safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity in adults with advanced solid tumors.

Johns Hopkins Medicine leads up to $52 million federal effort to study protein shapes and folding

Johns Hopkins Medicine
Grant and Award Announcement

A Johns Hopkins Medicine-led research team has received an award of up to $52.1 million over four years from the Advanced Research Projects Agency for Health (ARPA-H), part of the Department of Health and Human Services, to better understand the rules that decide what shape a protein takes — and how those rules could support the identification of earlier diagnostics and therapeutic targets when proteins fold the wrong way. The team will start this work, which will be publicly shared through open-access resources, by studying Parkinson’s disease and Ewing sarcoma, a rare cancer of bone and soft tissue in children and young adults.

Funder: Advanced Research Projects Agency for Health (ARPA-H)

Persistent nail separation may hide a rare melanoma

Higher Education Press
Peer-Reviewed Publication

A 71-year-old woman with a two-year history of a slowly deepening skin depression on her trunk was found to have atrophic dermatofibrosarcoma protuberans (DFSP)—a rare variant of skin cancer that mimics benign conditions such as scars or morphea. The case highlights the importance of biopsying firm, persistent atrophic lesions, as early diagnosis and complete surgical excision are key to preventing local recurrence.

Journal: Skin

SG research team develops novel nanobody targeting tumor-fueling fluid to treat late-stage cancer of the abdominal lining

SingHealth
Peer-Reviewed Publication

Peritoneal metastases, a late-stage cancer that has spread from the abdominal organs to the abdominal lining, is fuelled by surrounding fluid called ascites, but its molecular makeup has never been comprehensively mapped until now.

A study led by the National Cancer Centre Singapore (NCCS) analysed one of the largest ascites datasets in the world; 397 samples across 21 cancer types and identified two proteins, PAI-1 and S100A10, as key drivers of tumour growth.

Building on this, the team developed a novel nanobody, E8, targeting the protein PAI-1, and demonstrated the nanobody can suppress tumour growth in lab, animal, and human tissue models with minimal toxicity.

A new biologics programme, the Melyorax Initiative, will advance E8 and other novel treatment strategies towards clinical trials for patients who currently have limited treatment options.

Journal: Molecular Cancer

When cancer turns critical, the patient isn't the only one suffering

Flinders University
Peer-Reviewed Publication

While doctors fight to save the lives of cancer patients in intensive care, family members, partners and friends are often left carrying a heavy burden of their own, with research revealing widespread anxiety, depression, exhaustion and declining wellbeing among those supporting a loved one through a critical illness.

Journal: Intensive and Critical Care Nursing

Breast Cancer Awareness Month: Advancing breast cancer research through clinical trials

Alliance for Clinical Trials in Oncology
Business Announcement

Clinical trials play a vital role in progress against breast cancer. As part of the National Clinical Trials Network sponsored by the National Cancer Institute, the Alliance for Clinical Trials in Oncology works to advance cancer research and expand access to promising screening strategies and treatments. Through its clinical trials, the Alliance helps generate the evidence needed to improve care and bring better treatment options to patients. Today, the Alliance and Alliance Foundation Trials (AFT) have eight active trials open to people with breast cancer. Each represents another opportunity to advance research, improve care, and shape the future of breast cancer treatment.

Funder: Alliance for Clinical Trials in Oncology Foundation

17
18
19
20
21